A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine

Pediatr Infect Dis J. 2009 Apr;28(4):335-7. doi: 10.1097/INF.0b013e3181906351.

Abstract

After concomitant administration of purified chick embryo cell rabies vaccine and Japanese encephalitis vaccine to toddlers, adequate rabies and Japanese encephalitis virus neutralizing antibodies concentrations were demonstrated by day 49, 7 days after a booster at 1 year, and in the majorly at 3 years postvaccination. The inclusion of rabies vaccine in the expanded program on immunization should be considered in rabies endemic countries.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Antibodies, Viral / blood*
  • Chick Embryo
  • Humans
  • Immunization Schedule
  • Infant
  • Injections, Intradermal
  • Injections, Intramuscular
  • Japanese Encephalitis Vaccines* / administration & dosage
  • Japanese Encephalitis Vaccines* / adverse effects
  • Japanese Encephalitis Vaccines* / immunology
  • Neutralization Tests
  • Rabies Vaccines* / administration & dosage
  • Rabies Vaccines* / adverse effects
  • Rabies Vaccines* / immunology
  • Rabies virus / immunology*
  • Thailand

Substances

  • Antibodies, Viral
  • Japanese Encephalitis Vaccines
  • Rabies Vaccines